Anticoagulation and continuous renal replacement therapy

Seminars in Dialysis

Volumn 19, Issue 4, 2006, Pages 311-316

  Amanzadeh, Jamshid ^a,b   Reilly Jr , Robert F ^c  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ACUTE KIDNEY FAILURE; HUMAN; METHODOLOGY; RENAL REPLACEMENT THERAPY; REVIEW;

ACUTE KIDNEY INJURY; ANTICOAGULANTS; HUMANS; KIDNEY FAILURE, ACUTE; RENAL DIALYSIS;

EID: 33746237579     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2006.00178.x     Document Type: Review

References (57)

1. Mehta RL, Pascual MT, Soroko S, Savage BR, Himmelfarb J, Ikizler TA, Paganini EP, Chertow GM: Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int 66:1613-1621, 2004
2. Mehta RL, McDonald B, Gabbai FB, Pahl M, Pascual MT, Farkas A, Kaplan RM: A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. Kidney Int 60:1154-1163, 2001
3. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R: Continuous is not continuous: the incidence and impact of circuit "down-time" on uraemic control during continuous veno-venous haemofiltration. Intensive Care Med 29:575-578, 2003
4. Brophy PD, Somers MJ, Baum MA, Symons JM, McAfee N, Fortenberry JD, Rogers K, Barnett J, Blowey D, Baker C, Bunchman TE, Goldstein SL: Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT). Nephrol Dial Transplant 20:1416-1421, 2005
5. Baldwin I, Bellomo R, Koch B: Blood flow reductions during continuous renal replacement therapy and circuit life. Intensive Care Med 30:2074-2079, 2004
6. Ramesh Prasad GV, Palevsky PM, Burr R, Lesko JM, Gupta B, Greenberg A: Factors affecting system clotting in continuous renal replacement therapy: results of a randomized, controlled trial. Clin Nephrol 53:55-60, 2000
7. van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC: Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 7:145-150, 1996
8. Martin PY, Chevrolet JC, Suter P, Favre H: Anticoagulation in patients treated by continuous venovenous hemofiltration: a retrospective study. Am J Kidney Dis 24:806-812, 1994
9. Cardigan RA, McGloin H, Mackie IJ, Machin SJ, Singer M: Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration. Kidney Int 55:1568-1574, 1999
10. Salmon J, Cardigan R, Mackie I, Cohen SL, Machin S, Singer M: Continuous venovenous haemofiltration using polyacrylonitrile filters does not activate contact system and intrinsic coagulation pathways. Intensive Care Med 23:38-43, 1997
11. Singer M, McNally T, Screaton G, Mackie I, Machin S, Cohen SL: Heparin clearance during continuous veno-venous haemofiltration. Intensive Care Med 20:212-215, 1994
12. Klingel R, Schaefer M, Schwarting A, Himmelsbach F, Altes U, Uhlenbusch-Korwer I, Hafner G: Comparative analysis of procoagulatory activity of haemodialysis, haemo filtration and haemodiafiltration with a polysulfone membrane (APS) and with different modes of enoxaparin anticoagulation. Nephrol Dial Transplant 19:164-170, 2004
13. Bagshaw SM, Laupland KB, Boiteau PJ, Godinez-Luna T: Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system. J Crit Care 20:155-161, 2005
14. Morgera S, Scholle C, Voss G, Haase M, Vargas-Hein O, Krausch D, Melzer C, Rosseau S, Zuckermann-Becker H, Neumayer HH: Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: single-center experience. Nephron Clin Pract 97:c131-c136, 2004
15. Hofbauer R, Moser D, Frass M, Oberbauer R, Kaye AD, Wagner O, Kapiotis S, Druml W: Effect of anticoagulation on blood membrane interactions during hemodialysis. Kidney Int 56:1578-1583, 1999
16. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P: Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 30:260-265, 2004
17. Chadha V, Garg U, Warady BA, Alon US: Citrate clearance in children receiving continuous venovenous renal replacement therapy. Pediatr Nephrol 17:819-824, 2002
18. Brunton LL, Lazo JS, Parker KL: Goodman and Gilman's the Pharmacological Basis of Therapeutics, 11th ed. New York: McGraw-Hill, 2006
19. Hirsh J, Raschke R: Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:188S-203S, 2004
20. Nagge J, Crowther M, Hirsh J: Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 162:2605-2609, 2002
21. McMahon LP, Chester K, Walker RG: Effects of different dialysis membranes on serum concentrations of epoetin alfa, darbepoetin alfa, enoxaparin, and iron sucrose during dialysis. Am J Kidney Dis 44:509-516, 2004
22. Crowther MA, Berry LR, Monagle PT, Chan AK: Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 116:178-186, 2002
23. Hirsh J, Levine MN: Low molecular weight heparin. Blood 79:1-17, 1992
24. Ng HJ, Koh LP, Lee LH: Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin. Ann Hematol 82:257-258, 2003
25. Lim W, Cook DJ, Crowther MA: Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol 15:3192-3206, 2004
26. Reeves JH, Cumming AR, Gallagher L, O'Brien JL, Santamaria JD: A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med 27:2224-2228, 1999
27. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R: Continuous venovenous hemofiltration without anticoagulation. ASAIO J 50:76-80, 2004
28. Tan HK, Baldwin I, Bellomo R: Continuous veno-venous hemofiltration without anti coagulation in high-risk patients. Intensive Care Med 26:1652-1657, 2000
29. Bellomo R, Teede H, Boyce N: Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. Intensive Care Med 19:329-332, 1993
30. Morabito S, Guzzo I, Solazzo A, Muzi L, Luciani R, Pierucci A: Continuous renal replacement therapies, anticoagulation in the critically ill at high risk of bleeding. J Nephrol 16:566-571, 2003
31. Biancofiore G, Esposito M, Bindi L, Stefanini A, Bisa M, Boldrini A, Consani G, Filipponi F, Mosca F: Regional filter heparinization for continuous veno-venous hemofiltration in liver transplant recipients. Minerva Anestesiol 69:527-538, 2003
32. van der Voort PH, Gerritsen RT, Kuiper MA, Egbers PH, Kingma WP, Boerma EC: Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purif 23:175-180, 2005
33. Hetzel GR, Sucker C: The heparins: all a nephrologist should know. Nephrol Dial Transplant 20:2036-2042, 2005
34. Fischer KG: Hirudin in renal insufficiency. Semin Thromb Hemost 28:467-482, 2002
35. Diehl KH, Romisch J, Hein B, Jessel A, Ronneberger H, Paques EP: Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models. Haemostasis 25:182-192, 1995
36. Hein OV, von Heymann C, Morgera S, Konertz W, Ziemer S, Spies C: Protracted bleeding after hirudin anticoagulation for cardiac surgery in a patient with HIT II and chronic renal failure. Artif Organs 29:507-510, 2005
37. Frank RD, Farber H, Lanzmich R, Floege J, Kierdorf HP: In vitro studies on hirudin elimination by haemofiltration: comparison of three high-flux membranes. Nephrol Dial Transplant 17:1957-1963, 2002
38. Frank RD, Farber H, Stefanidis I, Lanzmich R, Kierdorf HP: Hirudin elimination by hemofiltration, a comparative in vitro study of different membranes. Kidney Int Suppl 72:S41-S45, 1999
39. Hein OV, von Heymann C, Diehl T, Ziemer S, Ronco C, Morgera S, Siebert G, Kox WJ, Neumayer HH, Spies C: Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Ren Fail 26:297-303, 2004
40. Vargas Hein O, von Heymann C, Lipps M, Ziemer S, Ronco C, Neumayer HH, Morgera S, Welte M, Kox WJ, Spies C: Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Med 27:673-679, 2001
41. McKeage K, Plosker GL: Argatroban. Drugs 61:515-522, 2001
42. Reddy BV, Grossman EJ, Trevino SA, Hursting MJ, Murray PT: Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy. Ann Pharmacother 39:1601-1605, 2005
43. Ota K, Akizawa T, Hirasawa Y, Agishi T, Matsui N: Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency. Nephrol Dial Transplant 18:1623-1630, 2003
44. Tang IY, Cox DS, Patel K, Reddy BV, Nahlik L, Trevino S, Murray PT: Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother 39:231-236, 2005
45. Kozek-Langenecker SA: Anticoagulation with prostaglandins during extracorporeal circulation. Wien Klin Wochenschr 111:129-140, 1999
46. Smith MC, Danviriyasup K, Crow JW, Cato AE, Park GD, Hassid A, Dunn MJ: Prostacyclin substitution for heparin in long-term hemodialysis. Am J Med 73:669-678, 1982
47. Kozek-Langenecker SA, Spiss CK, Michalek-Sauberer A, Felfernig M, Zimpfer M: Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration. Crit Care Med 31:864-868, 2003
48. Fiaccadori E, Maggiore U, Rotelli C, Minari M, Melfa L, Cappe G, Cabassi A: Continuous haemofiltration in acute renal failure with prostacyclin as the sole anti-haemostatic agent. Intensive Care Med 28:586-593, 2002
49. Balik M, Waldauf P, Plasil P, Pachl J: Prostacyclin versus citrate in continuous haemodiafiltration: an observational study in patients with high risk of bleeding. Blood Purif 23:325-329, 2005
50. Davenport A, Will EJ, Davison AM: Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure. Nephron 66:431-437, 1994
51. Kozek-Langenecker SA, Spiss CK, Gamsjager T, Domenig C, Zimpfer M: Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wien Klin Wochenschr 114:96-101, 2002
52. Langenecker SA, Felfernig M, Werba A, Mueller CM, Chiari A, Zimpfer M: Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Crit Care Med 22:1774-1781, 1994
53. Davenport A, Will EJ, Davison AM: The effect of prostacyclin on intracranial pressure in patients with acute hepatic and renal failure. Clin Nephrol 35:151-157, 1991
54. Davenport A, Will EJ, Davison AM: Adverse effects on cerebral perfusion of prostacyclin administered directly into patients with fulminant hepatic failure and acute renal failure. Nephron 59:449-454, 1991
55. Davenport A, Will EJ, Davison AM: Adverse effects of prostacyclin administered directly into patients with combined renal and respiratory failure prior to dialysis. Intensive Care Med 16:431-435, 1990
56. Inagaki O, Nishian Y, Iwaki R, Nakagawa K, Takamitsu Y, Fujita Y: Adsorption of nafamostat mesilate by hemodialysis membranes. Artif Organs 16:553-558, 1992
57. Akizawa T, Kitaoka T, Sato M, Koshikawa S, Hirasawa Y, Kazama M, Mimura N, Ota K: Comparative clinical trial of regional anticoagulation for hemodialysis. ASAIO Trans 34:176-178, 1988